Lebwohl, M., J. Sugarman, D. Pariser, J. Bagel, T. Lin, and R. Israel. “Safety and Tolerability of Fixed Combination Halobetasol Propionate 0.01% And Tazarotene 0.045% (HP/TAZ) Lotion in Patients With Moderate-to-Severe Plaque Psoriasis: Results From a 1-Year, Open-Label Study”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 1, Jan. 2020, p. S12, https://www.jofskin.org/index.php/skin/article/view/826.